Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

Video

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

<<< View more from 2019 ASH Annual Meeting

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Related Content
MCL | Image Credit: ©freshidea - stock.adobe.com

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

April 17th 2024
Article
Lori A. Leslie, MD

FDA Approval Insights: Pirtobrutinib in MCL

February 27th 2023
Podcast
CTL019 in MCL| Image Credit: © Dr_Microbe - stock.adobe.com

CTL019 Plus Ibrutinib is Feasible and Effective in Relapsed/Refractory MCL

March 29th 2024
Article
Joshua Brody, MD

Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL

December 8th 2022
Podcast
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024
Article
Cancer in the blood outbreak and treatment for malignant cells in a human body caused by carcinogens and genetics with a cancerous cell as an immunotherapy and leukemia or lymphoma symbol and medicalImage Credit: © freshidea - stock.adobe.com

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024
Article